 - Melanoma: Advanced or metastatic melanoma patients may be systemic therapy naïve or may have received systemic treatment for unresectable locally advanced or metastatic disease. A patient who previously received systemic therapy must have had progression on a checkpoint inhibitor e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4 as the most recent prior therapy. 